Red Flags
- Diabetes with established ASCVD and LDL-C above goal on maximally tolerated statin — add ezetimibe; PCSK9 inhibitor if not at <55 mg/dL[1]
- Triglycerides ≥1000 mg/dL with diabetes — risk of acute pancreatitis; urgent fibrate plus lifestyle, glycaemic control[1]
- Diabetes with familial hypercholesterolaemia features (LDL-C ≥190, tendon xanthomas, family history of premature CAD) — high-intensity statin and family cascade screening[1]
- Statin myopathy with diabetes (severe muscle symptoms with CK >5× ULN) — pause statin; investigate; switch class or use ezetimibe / bempedoic acid alternative[1]
First-line treatment
Interventions
- Lifestyle modification with diabetes focus[1]Mediterranean-style diet emphasising plant fats, oily fish; weight reduction 5–10% if overweight; ≥150 min/week aerobic activity; smoking cessation; alcohol moderation; medical nutrition therapy
First-line drug therapy
| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Atorvastatin[1] | HMG-CoA reductase inhibitor (high-intensity) | 40–80 mg PO once daily for high-risk; 10–20 mg moderate-intensity for primary prevention without other risk | — | First-line for all adults with diabetes age ≥40 regardless of LDL-C; LDL-C goal <55 mg/dL very-high-risk ASCVD, <70 high-risk |
| Rosuvastatin[1] | HMG-CoA reductase inhibitor | 20–40 mg PO daily (high-intensity); 5–10 mg moderate | — | Alternative; preferred in renal impairment (less hepatic metabolism) |
| Ezetimibe[1] | Cholesterol absorption inhibitor | 10 mg PO once daily | — | Add when statin alone insufficient; ~20% additional LDL-C reduction; combined statin + ezetimibe offers similar LDL-C lowering with less statin |
| Fenofibrate[1] | Fibrate | 145–160 mg PO once daily | — | For severe hypertriglyceridaemia (TG ≥500); reduces pancreatitis risk; modest benefit on dual-dyslipidaemia in T2DM (FIELD subgroup) |
| Icosapent ethyl (high-dose EPA)[1] | Omega-3 fatty acid (purified EPA) | 2 g PO BD with meals | — | Add for diabetes with TG 135–500 on optimal statin; reduces cardiovascular events per REDUCE-IT |
| Evolocumab or alirocumab (PCSK9 inhibitors)[1] | Monoclonal antibody (anti-PCSK9) | Evolocumab 140 mg SC every 2 weeks OR 420 mg SC monthly; alirocumab 75–150 mg SC every 2 weeks | — | For very-high-risk diabetes ASCVD not at LDL-C goal on maximally tolerated statin + ezetimibe |
Atorvastatin[1]
HMG-CoA reductase inhibitor (high-intensity)
- Adult
- 40–80 mg PO once daily for high-risk; 10–20 mg moderate-intensity for primary prevention without other risk
- Paediatric
- —
First-line for all adults with diabetes age ≥40 regardless of LDL-C; LDL-C goal <55 mg/dL very-high-risk ASCVD, <70 high-risk
Rosuvastatin[1]
HMG-CoA reductase inhibitor
- Adult
- 20–40 mg PO daily (high-intensity); 5–10 mg moderate
- Paediatric
- —
Alternative; preferred in renal impairment (less hepatic metabolism)
Ezetimibe[1]
Cholesterol absorption inhibitor
- Adult
- 10 mg PO once daily
- Paediatric
- —
Add when statin alone insufficient; ~20% additional LDL-C reduction; combined statin + ezetimibe offers similar LDL-C lowering with less statin
Fenofibrate[1]
Fibrate
- Adult
- 145–160 mg PO once daily
- Paediatric
- —
For severe hypertriglyceridaemia (TG ≥500); reduces pancreatitis risk; modest benefit on dual-dyslipidaemia in T2DM (FIELD subgroup)
Icosapent ethyl (high-dose EPA)[1]
Omega-3 fatty acid (purified EPA)
- Adult
- 2 g PO BD with meals
- Paediatric
- —
Add for diabetes with TG 135–500 on optimal statin; reduces cardiovascular events per REDUCE-IT
Evolocumab or alirocumab (PCSK9 inhibitors)[1]
Monoclonal antibody (anti-PCSK9)
- Adult
- Evolocumab 140 mg SC every 2 weeks OR 420 mg SC monthly; alirocumab 75–150 mg SC every 2 weeks
- Paediatric
- —
For very-high-risk diabetes ASCVD not at LDL-C goal on maximally tolerated statin + ezetimibe
Safety-net
- Statins are taken lifelong even if blood tests look good — they reduce heart attack and stroke independent of cholesterol level alone[1]
- Mild muscle aches are common; severe muscle pain or dark urine — pause statin and seek care[1]
- Triglycerides above 500 mg/dL with abdominal pain — call emergency services (pancreatitis risk)[1]
Referral criteria
- Triglycerides ≥1000 mg/dL with abdominal painEmergency department for acute pancreatitis evaluation[1]
- Suspected familial hypercholesterolaemia in diabetes (LDL-C ≥190, tendon xanthomas, premature CAD family history)Lipid clinic for genetic testing and family cascade screening[1]
- Diabetes with established ASCVD not at LDL-C goal <55 mg/dL on maximally tolerated statin + ezetimibeLipid clinic / cardiology for PCSK9 inhibitor[1]
- Statin intolerance with multiple statinsLipid clinic for bempedoic acid, ezetimibe, or PCSK9 inhibitor alternatives[1]
Clinical summary
Diabetes-specific dyslipidaemia management — small dense LDL pattern, atherogenic lipid triad; high-intensity statin plus combination therapy for very-high-risk.